By Peter Geschek:Even with the best cancer drugs, doctors are forced to switch from one therapy to the next as the tumors rapidly develop resistance.A new wave of immunotherapy drugs, in the spotlight of the upcoming ASCO (American Society of Clinica

By Investment Directions: We had great news today (Thursday), but the response was tepid. Rather than being disappointed or dismissing the news, here is why we should be excited at both the developments and the investment potential it opens up. Thurs

Researchers reported that a combination of two drugs from Bristol-Myers Squibb appeared to shrink tumors in 41 percent of patients in a small study.    

Two early-stage drug studies from Bristol-Myers and Roche provided fresh evidence that harnessing the power of the immune system is emerging as a promising weapon against cancer.

Positive results from two early-stage studies of drugs from Bristol-Myers Squibb Co. (BMY) and Roche Holding AG (RHHBY) provided fresh evidence that the power of the immune system is emerging as a promising new weapon against cancer.

CHICAGO, May 15 (Reuters) - Melanoma patients treated with two Bristol-Myers Squibb drugs fared much better than those who received either of the medications individually, a new advance for...

The speculation centers around Bristol-Myers' cancer trial results.

CHICAGO/NEW YORK (Reuters) - Shares of drugmaker Bristol-Myers Squibb Co rose to a 10-year high on Wednesday ahead of results of an early stage trial for its new melanoma treatment, with heavy...

CHICAGO/NEW YORK, May 15 (Reuters) - Shares of drugmaker Bristol-Myers Squibb Co rose to a 10-year high on Wednesday ahead of results of an early stage trial for its new melanoma treatment, with...

CHICAGO/NEW YORK, May 15 (Reuters) - Shares of drugmaker Bristol-Myers Squibb Co rose to a ten-year high on Wednesday ahead of results of an early stage trial for its new melanoma treatment, with...

By Interactive Brokers: BMY - Bristol-Myers Squibb Co. - Shares in drug maker, Bristol-Myers Squibb Co., are ripping higher today, up 6.5% at $44.94, the highest level in more than a decade, ahead of the release of the American Society of Clinical On

ByBio Matt:Bristol-Myers (NYSE:BMY)Bristol-Myers recently reported its Q1 2013 financial results with a 27% decline in pharmaceutical revenues towards Q1 2012, but with a 10% increase excluding Avapro and Plavix. The Eliquis launch has also been slig

Ambrx today entered into a collaboration agreement with Bristol-Myers Squibb (NYSE: BMY) for the discovery and development of novel antibody drug conjugates using Ambrx's protein medicinal chemistry technology.Under terms of the agreement, Ambrx will

Investors who have shunned the safety of the crowd and bet on Bristol-Myers Squibb will soon know whether they have been bold or foolhardy

Bristol-Myers Squibb Company (BMY)Q1 2013 Earnings Conference CallApril 25, 2013 10:30 ETExecutivesJohn Elicker - Senior Vice President, Investor Relations and Public AffairsCharlie Bancroft - Chief Financial OfficerElliott Sigal - Chief Scientific O

(Reuters) - Bristol-Myers Squibb reported disappointing first-quarter sales, prompting a drop in shares that have risen sharply this year on enthusiasm for its lineup of promising experimental drugs.

Bristol-Myers Squibb reported a nearly 45% decline in first-quarter profit, as the loss of patent protection for formerly big-selling heart drugs continued to pressure sales.

April 25 (Reuters) - Bristol-Myers Squibb's first-quarter earnings plunged 45 percent on generic competition for its drugs, but surprisingly low taxes enabled the company to meet Wall Street's forecast.

NEW YORK (MarketWatch) -- Bristol-Myers Squibb Co. said Thursday its first-quarter profit fell 45% to $609 million, or 37 cents a share, from $1.1 billion, or 64 cents a share, a year earlier. Net sales fell 27% to $3.83 billion, from $5.25 billion a

April 25 (Reuters) - Bristol-Myers Squibb Co reported lower first-quarter earnings, in line with forecasts, thanks to unexpectedly lower taxes and sharply higher sales of its treatments for melanoma, leukemia and diabetes.

April 25 (Reuters) - Bristol-Myers Squibb Co reported lower first-quarter earnings, in line with forecasts, thanks to unexpectedly lower taxes and sharply higher sales of its treatments for melanoma, leukemia and diabetes.

By WhisperNumber: Bristol-Myers Squibb (BMY) is expected to report earnings on Thursday, April 25th. The whisper number is $0.45, four cents ahead of the analysts' estimate. BMY has a 46% positive surprise history (having topped the whisper in 11 of

By Trefis: Bristol-Myers Squibb(BMY) is scheduled to announce its results for Q1 2013 on April25. All eyes will be on the performance of its new drugs, which will bethe key drivers of revenue growth going forward. The company has startedto feel the p

Can Bristol-Myers go from also-ran to the eventual hep-C champ?

In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, Bristol-Myers Squibb Co. (NYSE: BMY) has taken over the #44 spot from Union Pacific Corp (NYSE: UNP), according to The Online Investor. Click

Here's your Cheat Sheet to earnings...

* Bristol-Myers shares up 1.2 percent after promising data

* Bristol-Myers shares up 1.2 percent after promising data

Analysts have become increasingly bearish on Bristol Myers Squibb (BMY) in the month leading up to the company's first quarter earnings announcement scheduled for Thursday, April 25, 2013. The consensus analyst estimate has moved from 43 cents a

AMSTERDAM (TheStreet) -- Hepatitis C drug developers dumped a ton of clinical data on investors this morning as a liver disease meeting gets underway in Amsterdam. An experimental triple combination therapy from Bristol-Myers Squibbappears a bit stro

* 2 serious side effects likely unconnected to Bristol drugs

* 2 serious side effects likely unconnected to Bristol drugs

Merck and Bristol-Myers Squibb are the latest to join forces.

Barron's recently posted Citi's updated list of large, financially strong, high yielding, dividend paying companies. Three drug companies make the grade: Pfizer (NYSE: PFE), Merck (NYSE: MRK), and Bristol Myers (NYSE: BMY).

April 11 (Reuters) - Bristol-Myers Squibb Co said on Thursday it plans to spend $250 million to expand its Devens, Massachusetts, facility that makes large-scale biologic drugs.

April 11 (Reuters) - Bristol-Myers Squibb Co said on Thursday it plans to spend $250 million to expand its Devens, Massachusetts, facility that makes large-scale biologic drugs.

April 11 (Reuters) - Bristol-Myers Squibb Co on Thursday said it plans to spend $250 million to expand its Devens, Massachusetts, facility that makes large-scale biologic drugs.

April 11 (Reuters) - Bristol-Myers Squibb Co on Thursday said it plans to spend $250 million to expand its Devens, Massachusetts, facility that makes large-scale biologic drugs.

April 11 (Reuters) - Bristol-Myers Squibb Co on Thursday said it plans to spend $250 million to expand its Devens, Massachusetts, facility that makes large-scale biologic drugs.

April 11 (Reuters) - Bristol-Myers Squibb Co on Thursday said it plans to spend $250 million to expand its Devens, Massachusetts, facility that makes large-scale biologic drugs.

Bristol-Myers Squibb (NYSE: BMY) today announced plans for an approximately$250 million expansion of its large-scale biologics manufacturing facility inDevens, Massachusetts.

By Jim Van Meerten: A right time to buy a good stock is during a market pullback, which is right now. The shares of Bristol-Myers Squibb (BMY) have pulled back a little so if you've been waiting now is a good time to step in. During the past 6 months

In a report published Monday, BMO Capital Markets analyst Alex Arfaei reiterated a Market Perform rating on Bristol Myers Squibb Co.

April 8 (Reuters) - BRISTOL-MYERS: * Bristol-Myers CEO says research chief Elliott Sigal mentioned a few months ago his interest in retiring * Bristol-Myers CEO says in conference call that Sigal retiring after successful launch of Eliquis blood clot

ByBio Matt:Bristol-Myers 2012 RecapBristol-Myers Squibb (NYSE:BMY) has had a fantastic start to 2013 so far, with the stock's PPS up about 24% since Jan 2nd. 2012 saw strong growth from immuno-Oncology brands such as Orencia, Yervoy, Sprycel, and Erb

Francis Cuss will head research and development at drug maker Bristol-Myers, succeeding Elliott Sigal, who is retiring.

April 7 (Reuters) - U.S. drugmaker Bristol-Myers Squibb Co said on Sunday it has named Francis Cuss to become its next chief scientific officer after Elliott Sigal retires as head of research and development on June 30.